Altogether, these results indicate that TGF-β inhibition could enhance the therapeutic efficacy of anti-PD-1 against EGFR-TKI resistant NSCLC, highlighting the potential of a new combined immunotherapy strategy for EGFR-mutated NSCLC patients after EGFR-TKI failure. Here, PDCD1 is linked to non-small cell lung carcinoma.